Reflection on clinical and methodological issues in rare disease clinical trials

1:1
Experts provide a comprehensive reflection on the unique clinical and methodological challenges inherent in designing and executing trials for rare diseases.

This paper discusses the specific hurdles faced in rare disease research, including small patient populations and recruitment difficulties. It reflects on innovative trial designs and statistical methods that can enhance the robustness of clinical evidence in these settings.

Source

Orphanet Journal of Rare Diseases

You might also be interested in

A new online learning series for ERN professionals, clinicians, researchers, and stakeholders.
The session will introduce the workstream’s activities in data sharing, systematic diagnostic reanalysis, advanced diagnostic pipelines, and genomic and multi-omics innovation.
This initiative is also highly relevant from a rare diseases perspective, as paediatric cancers are rare conditions where small patient populations make robust non‑clinical proof‑of‑concept data essential for responsible and ethical trial initiation.
For rare diseases, where research often relies on limited animal models and small development teams, the regulatory acceptance of virtual control groups could help streamline early non‑clinical studies while maintaining a strong focus on patient safety.